254 results about "Specific immunity" patented technology

The invention discloses a toxoplasma gondii attenuated vaccine strain RH delta rop67 as well as a construction method and application thereof, and belongs to the technical field of parasitic disease prevention and control and biological product preparation. The attenuated vaccine strain is constructed by performing targeted knockout on the ROP67 gene in a toxoplasma gondii strain RH delta ku80 through a CRISPR / Cas9 mediated gene editing technology. Compared with a wild type strain, the attenuated vaccine strain shows remarkable attenuation characteristic and good immunogenicity. A test result shows that the attenuated vaccine strain can induce a host to generate specific immune response mainly based on cellular immunity, maintains a protection effect on toxoplasma gondii infection in a relatively long immune period, and has a protection effect on tachyzoite infection and a chronic infection stage of toxoplasma gondii strains with different virulence; the survival ability of a host to tachyzoite infection can be improved, and the formation level of cysts in tissues is reduced. The invention provides a technical scheme with long-term immune potential for research and development of toxoplasma gondii attenuated vaccines.

The invention relates to a composition for treating large yellow croaker pyramidoniasis as well as a preparation method and application thereof, and belongs to the technical field of aquaculture. The composition comprises the following components: curcumin, bile acid, beta glucan, bacillus subtilis freeze-dried powder, marine red yeast freeze-dried powder, vitamin C, vitamin E and ethylicin. When the feed additive is added into basal feed to feed large yellow croakers infected with the trypanosomiasis, the death rate of sick fishes can be effectively reduced, the polypide loading capacity is remarkably reduced, and pathological injuries of livers and spleens of the large yellow croakers are relieved. In addition, the composition can also improve the non-specific immunity of the fish body, improve the liver function, enhance the antioxidant capacity of the liver, and improve the lipase activity of the intestinal tract at the same time. Therefore, the composition can be used as a medicine or a feed additive for treating the large yellow croaker pyramidoniasis, has the advantages of small dosage and remarkable effect, and provides a new technical approach for solving the problem that the current large yellow croaker pyramidoniasis lacks an effective prevention and control means.

The present invention relates to an antigenic peptide targeting FLT3-D835 mutation and its application in tumor immunotherapy. Specifically, the present invention provides an antigenic peptide for eliciting an immune response targeting FLT3-D835 mutation. Compared with the lack of affinity between the wild-type polypeptide and HLA-A * 02:01 molecule, the antigenic peptide of the present invention has high affinity for HLA-A * 02:01 molecule. The present invention also provides the application of the antigenic peptide of the present invention. The antigenic peptide of the present invention has good immunogenicity, can activate specific immune responses, and has important clinical significance for targeting the clearance of leukemia cells, stabilizing the remission state of AML patients, and prolonging the disease-free survival time.

The invention provides a bacillus subtilis strain and application thereof, the bacillus subtilis strain is named as bacillus subtilis Ya3.1, is preserved in China General Microbiological Culture Collection Center on July 7, 2025, and has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.35019; the bacillus subtilis Ya3.1 is separated from intestinal tracts of healthy hybrid sturgeons, and can be used as a probiotic additive for aquaculture, especially for sturgeon culture. The bacillus subtilis Ya3.1 provided by the invention has high safety, strong stress resistance and efficient intestinal colonization ability, and can significantly improve the activity of sturgeon intestinal digestive enzymes, improve the growth performance of sturgeons, enhance the non-specific immunity of sturgeons, improve the intestinal flora structure and significantly improve the ability to resist aeromonas bacterial infection; and a special probiotic resource can be provided for sturgeon culture.

The invention relates to a fungus-diatom synergistic immunopotentiator for stichopus japonicus, and belongs to the technical field of microbial engineering and echinoderm immunology. The immunopotentiator is a symbiont microsphere taking yarrowia lipolytica and navicula seminuda as main components; the method comprises the following steps: respectively activating yarrowia lipolytica and navicula seminuda, carrying out expanding culture, resuspending, and adjusting the concentrations of a bacterial solution and algae cells; the preparation method comprises the following steps: adding a navicula seminuda concentrated solution and a yarrowia lipolytica suspension into a triangular flask containing a YPD liquid culture medium, adding selenium-containing fucoidan polysaccharide sulfate accounting for 0.4-1.2% of the total mass of microspheres, carrying out constant-temperature shake culture, filtering by using sterile gauze to obtain microspheres, and flushing by using sterile normal saline to obtain fungus-diatom symbiont microspheres; the yarrowia lipolytica, the navicula seminuda and the selenium-containing fucoidan polysaccharide sulfate in the prepared immunopotentiator are mutually beneficial and have a synergistic effect, and the non-specific immune function of the stichopus japonicus is comprehensively improved by improving the growth index, enhancing the activity of immune enzyme and digestive enzyme and improving the disease resistance.

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.

The present invention relates to a recombinant chimeric antigen targeting poxvirus (particularly monkeypox virus), a subunit vaccine thereof, and its application. The recombinant chimeric antigen of the present invention comprises two immunogens arranged in a specific manner: monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment) and monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), which can stimulate immune responses against two infectious virus particles: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently stimulating specific immune protection against monkeypox virus. In addition, the poxvirus vaccine of the present invention also has good safety, rapid responsiveness and production capacity support, and has excellent clinical application prospects.

The invention belongs to the technical field of medicine detection, and particularly relates to a method for reducing a HOOK effect in colloidal gold immunochromatography detection and application. The upstream of the T line is provided with the B line, the B line is coated with the first antibody which is not marked, the combination pad is coated with the first antibody which is marked by colloidal gold, and the first antibody which is marked by colloidal gold and the first antibody which is not marked can be specifically combined with an analyte antigen in a sample to be detected; in addition, the T line is coated with a second antibody, the second antibody and a first antibody marked by colloidal gold, and the unmarked first antibody is a pair of antibodies capable of performing specific immunoreaction with different epitopes of the same antigen. According to the invention, due to the arrangement of the B line, the competitive strength of a large number of free analyte antigens and gold-labeled antibody-analyte antigen compounds on the binding site of the T line is favorably reduced, so that the HOOK effect is reduced, and the detection accuracy is remarkably improved.

Disclosed in the present invention are an ultrasonic therapy system and use thereof. The ultrasonic therapy system comprises a host and a therapy head. The host comprises a signal module, a power supply module, an output module, and a matching module. The therapy head comprises a piezoelectric module and an amplitude transformer module. The length of the piezoelectric module and the length of the amplitude transformer module are half of the wavelength. The output frequency range of the ultrasonic therapy system conforms to the frequency range of ultrasonic waves output by bats. According to the present invention, low-frequency low-intensity ultrasonic acts on the immune system of an organism, and specific immune environments featuring high interferon α expression, strong immune response, enhanced autophagy, down-regulated inflammation level, etc., are formed in the organism. Therefore, the ultrasonic therapy system can be used to resist tumors and viruses, prevent and ameliorate inflammatory aging, prolong the lifespan, and treat autoimmune diseases.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus, an immunogenic composition containing the recombinant chimeric antigen and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises two immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122 and ORF060 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and cell outer enveloped virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

This invention discloses a recombinant adenovirus vaccine targeting the Tp0326 antigen and its preparation method, comprising a recombinant adenovirus vector and the Tp0326 antigen expressed therein. The recombinant adenovirus vector uses a replication-defective human adenovirus type 5 (Ad5) as a backbone, inserting the full-length Tp0326 antigen gene of *Treponema pallidum* into the adenovirus shuttle vector pshuttle-IRES-rGFP-1, and obtaining it through homologous recombination with the adenovirus backbone plasmid pAdEasy-1. This invention, using a replication-defective Ad5 as a vector, provides a recombinant adenovirus vaccine with high safety and efficient expression of the full-length Tp0326 antigen. The expressed antigen has a natural conformation, retains the ECL4 immunodominant epitope, and is more likely to induce a specific immune response, resulting in stronger immunogenicity. The preparation method involves constructing a recombinant adenovirus vector through homologous recombination, packaging it in HEK293T cells, and purifying it by CsCl density gradient centrifugation to obtain a high-purity, high-titer recombinant adenovirus vaccine suitable for large-scale production. The recombinant adenovirus vaccine can be administered via intramuscular or intranasal injection.

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.

The invention relates to a pTau antigen compound of an AP205 or Lus protein nanoparticle carrier, a vaccine containing the pTau antigen compound as well as a preparation method and application of the pTau antigen compound. According to the pTau antigen compound disclosed by the invention, pTau antigen epitope peptide is efficiently loaded on a protein nanoparticle carrier by utilizing a specific SpyCatcher-SpyTag biological coupling system and is self-assembled to form a 180 / 60 polymer spherical structure, so that the pTau antigen epitope peptide is displayed on the surface of the spherical structure to form an ordered and repeated antigen array; therefore, an organism can be stimulated to generate specific immune response aiming at pTau protein to the greatest extent, and the immunogenicity is relatively high; the vaccine based on the pTau antigen compound can induce an organism to generate a high-titer pTau antibody, and cannot induce generation of T cell reaction aiming at pTau, so that the vaccine has relatively high safety.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The present invention provides a protein detection method and detection preparation, which realizes efficient enrichment of target protein through mesoporous silica-graphene oxide composite nanoporous material, completes specific immune capture in combination with magnetic nanoparticles modified with targeted antibodies, and realizes single molecule separation using a microfluidic chip of a three-dimensional hydrogel antibody array. Signal amplification adopts enzyme-labeled secondary antibody-gold nanorod conjugate, enhances the fluorescence signal through the plasma resonance effect, and corrects the background noise in combination with a convolutional neural network algorithm, which significantly improves the detection reliability; experiments show that the detection limit of this method is as low as 0.12pg / mL, the linear range covers 0.5-100,000pg / mL, the single cell detection error is ±7.8%, the batch repeatability (CV=4.2%), the nonspecific adsorption rate is only 1.1%, and the detection time is shortened to 1.2 hours. The detection method of the present invention is suitable for ultra-sensitive detection of tumor markers, especially in the in situ analysis of CTCs with clinical application potential.

The invention relates to the field of animal nutrition additives, and particularly discloses an animal additive based on probiotic synergistic fermentation sea buckthorn residue and hermetia illucens protein and a preparation method thereof, the animal additive comprises the following components by mass: 5%-10% of a filling auxiliary material, and the balance of a fermentation composite product; the sea-buckthorn residues and the hermetia illucens larvae can be fermented to form a double-substrate fermentation product, so that the double-substrate fermentation product has a synergistic nutrition effect, and can be used for remarkably promoting the weight gain condition of animals, improving spleen and thymus indexes and increasing serum IgG and IgM; the hermetia illucens protein is rich in lauric acid, antibacterial peptide and high-quality animal protein, so that the non-specific immunity and the anti-stress capability of an organism are enhanced, and the infection risk in the breeding process is reduced; the low-value sea-buckthorn residues and the hermetia illucens larvae are upgraded and converted into high-value feeding resources in a biological fermentation mode, the environmental pressure of processing by-products is relieved, the additional value of raw materials is increased, and the method conforms to resource circulation and environmental protection policy guidance.

The invention discloses a virus-like particle coated with an aluminum-containing metal organic framework mineralization layer and application of the virus-like particle. In order to improve the VLPs vaccine stability and immune effect, the invention synthesizes a novel aluminum-containing metal organic framework (ZAM). The ZAM can mineralize the VLPs at a high level under a mild condition to form the VLPs-ZAM nano vaccine. Taking a foot and mouth disease virus (FMDV) virus-like particle (VLPs) vaccine as an example, a heat treatment test shows that ZAM mineralization significantly improves the heat stability of FMDVVLPs, and the effect is superior to that of Al (OH) 3 and ZIF-8. The FMDV VLPs-ZAM not only has the effect of promoting APCs to take in FMDVVLPs, but also can promote antigens to escape from lysosome to cytoplasm due to the pH responsiveness of the FMDV VLPs-ZAM. A mouse immune test shows that ZAM mineralization improves the specific immune response level and stability induced by FMDV VLPs. The invention provides a new technical means for improving the stability of the VLPs vaccine and the immune effect of the VLPs vaccine.

The present invention relates to: a feed composition for zooplankton, comprising biomass derived from Schizochytrium sp. microalgae; a method for culturing zooplankton using same; and an aquaculture method for fish or crustaceans. The biomass derived from Schizochytrium sp. microalgae of the present invention has the effect of nutritionally enriching zooplankton, and when zooplankton fed with the biomass is fed to fish or crustaceans, growth of fish or crustaceans is promoted and non-specific immunity is enhanced, and thus the biomass can be effectively used as a feed composition or a feed additive.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

This application discloses a spatial segmentation radiotherapy guidance method and system based on target immune region activation, relating to the field of digital electrophysiological data processing. The method achieves three-dimensional visualization of metabolic activity and immune response through multimodal fusion of spectral CT / functional magnetic resonance imaging and ResNet radiomics feature extraction, which significantly improves the recognition accuracy compared to anatomical target volume. Furthermore, the immune thermogram generated by the XGBoost model and SAMed-2 segmentation markers can accurately locate highly immune-responsive voxels, and the Monte Carlo simulation gradient dose distribution ensures that the dose intensity in the immune-activated region is several times that of the conventional region while protecting the inactive region. The XGBoost model training of this application can dynamically adjust the dose hotspot according to the patient's specific immune characteristics, so that the radiation can accurately and sufficiently reach the region in the tumor area that is most capable of activating the immune system.

In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and / or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer; an antigen disposed within or attached to said biocompatible polymer where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a first targeting moiety that binds to a scavenger receptor in the liver, and / or a second targeting moiety that binds to a mannose receptor in the liver, and / or a third targeting moiety that binds to hepatocytes, wherein said first and / or second and / or third targeting moiety are attached to the surface of said nanoparticle.

Provided is a pharmaceutical composition for use in inducing an antigen-specific immune response, the pharmaceutical composition comprising: a polyrotaxane having a plurality of macroring molecules, an axis molecule that penetrates the rings of the macroring molecules, and caps that bind to the ends of the axis molecule, in which at least some of the macroring molecules include an amine-containing group having a monovalent proton at neutral pH and a divalent proton at acidic pH; and an antigen.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The present invention belongs to the field of pharmaceutical technology, and particularly relates to an immune-activating antibody and its application. The immune-activating antibody provided by the present invention comprises an antibody and an immune activator coupled by a coupling chain, and can be used for preparing anti-tumor drugs, anti-viral drugs, immunomodulatory drugs and / or preparations for eliminating target proteins. By coupling the antibody and the immune activator through the coupling chain, a series of immune-activating antibodies targeting specific tissues, lesions and targets can be formed, which can achieve the effect of locally targeted immune activation, solve the negative impact of TLR activation on normal tissues, and have good specific immune regulation and therapeutic effects.

The invention discloses a CD176 oral vaccine immunologic adjuvant and an application thereof, the CD176 oral vaccine immunologic adjuvant comprises a lucid ganoderma component, and the lucid ganoderma component is used as the immunologic adjuvant, so that the immune efficacy of an oral CD176 vaccine can be remarkably enhanced, the specific immune response is improved and enhanced, and more effective immune protection is provided for an organism.

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).

The disclosure pertains to conformational epitopes in alpha-synuclein, antibodies thereto and methods of making and using immunogens and antibodies specific thereto. In particular antibodies raised to cyclic compounds comprising at least 3 amino acids of EKTKEQ (SEQ ID NO: 1) selectively recognize misfolded oligomeric alpha-synuclein and are able to inhibit alpha-synuclein propagation and toxicity.

The present invention relates to tumor-specific immune cell markers and their uses. Specifically, an immune cell marker combination is provided, comprising: (1) an immune cell activation marker, and (2) an immune cell inhibition marker, optionally further comprising (3) an intracellular marker, and / or (4) a tissue-resident memory marker. The marker combination of the present invention can more accurately identify and enrich tumor-specific immune cells, and the enriched cell population has better tumor reactivity and tumor killing function.

The present invention relates to a combined treatment composition for tumor treatment and a combined treatment method. The combined treatment composition or a medicine kit comprises a therapeutically effective amount of a platinum chemotherapeutic drug, and a therapeutically effective amount of CpG oligonucleotide and a therapeutically effective amount of R848. The present invention further provides a combined treatment method for treating a tumor by means of the combined treatment composition or the medicine kit. Firstly, a low-dose chemotherapeutic drug is used to kill a tumor so as to release a tumor neoantigen, such that a body immune system autonomously identifies and screens the neoantigen, and then CpG oligonucleotide and an R848 activator of immune response are used to induce and promote the body to generate immune response specific to the tumor neoantigen, such that the anti-tumor function of T cells is improved and enhanced, thereby achieving the effect of inhibiting tumor growth.

The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.